Form 4: Syndax Pharmaceuticals Director Huber Receives 25,000 Restricted Stock Units

Director Martin H. Huber Jr. of Syndax Pharmaceuticals Inc. reports the acquisition of 25,000 restricted stock units on February 5, 2025.

Summary

• On February 5, 2025, Martin H. Huber Jr., a director of Syndax Pharmaceuticals Inc., acquired 25,000 shares of common stock in the form of restricted stock units.
• These restricted stock units were awarded at a price of $0.
• Following this transaction, Huber directly owns 74,000 shares of Syndax Pharmaceuticals Inc.
• The restricted stock units vest one year from the date of grant but cannot be transferred or sold until separation from service, death, disability, or a change in control.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The granting of stock units is generally seen as a positive sign, aligning management interests with shareholders, but it's a routine event.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The restricted stock units vest one year from the date of grant, suggesting a commitment to the company's long-term performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings of company insiders.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating that a director's interests are aligned with theirs.

Key Dates